Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin

Abstract

For HCC patients, although miriplatin-TACE was superior to epirubicin-TACE in the short term, it proved inferior to the latter in the long term. The merits of TACE using miriplatin should be further investigated, because adverse effects appear to be minimal after miriplatin administration.

Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma

“…The prospective study design and rigid evaluation are strengths in the present study. Prior to this study, there were three retrospective studies that compared the local control efficacy of TACE for HCC with miriplatin or epirubicin . In those studies, one study showed that the local control effects of TACE for HCC using miriplatin was significantly less than those using epirubicin .…”

“…Therefore, it cannot sufficiently flow into small feeding arteries of the tumor because of that high viscosity of the miriplatin–iodized oil suspension . In the previous controlled studies, a warmed miriplatin–iodized oil suspension was not administered . Seko et al reported the efficacy of TACE using miriplatin according to temperature conditions, for example, 44.3% of the patients treated with room temperature miriplatin, and 71.1% of the patients who received warmed miriplatin experienced CR or PR.…”

“…Recently, we were able to use a novel lipophilic cisplatin derivative that can be suspended in Lipiodol, an oily lymphographic agent: miriplatin ([SP‐4‐2]‐[(1R, 2R)‐cyclohexane‐1, 2‐diamine‐N, N]‐bis [tetradecanoate‐O] platinum monohydrate) (Dainippon Sumitomo Pharmaceutical Co., Ltd., Osaka, Japan) . Because miriplatin has an ideal pharmacological structure in the treatment of HCC with Lipiodol using TACE, there are several reports of the usefulness of miriplatin in this procedure . However, Iwazawa et al reported in their retrospective study that the local control effects of TACE for HCC using miriplatin is significantly less than those using epirubicin.…”

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma

“…It has also been reported that the local control rate is higher with epirubicin compared with miriplatin (22). However, the short-term effects of miriplatin and epirubicin are reported to be comparable (23). In the present study of BCLC-B HCC, in terms of tumor factors, it was clear that up-to-seven criteria and hepatic reserve play a role in survival; in terms of tumor treatment factors, the combined use of DDP-H and miriplatin contributed to improved survival.…”

Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma

“…Miriplatin ([SP‐4‐2]‐[(1R, 2R)‐Cyclohexane‐1,2‐diamine‐N,N′]‐bis (tetradecanoato‐O) platinum monohydrate (Dainippon Sumitomo Pharmaceutical Co. Ltd., Osaka, Japan) is a novel lipophilic cisplatin derivative that can be suspended in lipiodol, an oily lymphographic agent . Several studies have reported the usefulness of miriplatin at the time of TACE therapy for HCC . Although miriplatin seemed to have an ideal chemical and pharmacological structure in the treatment of HCC with lipiodol‐using TACE, Miyayama et al .…”